Mondkapje in ZGT verplicht Let op: het dragen van een mondkapje is voor alle patiënten, bezoekers en begeleiders vanaf 12 jaar in ZGT verplicht. Een faceshield mag alleen aanvullend worden gebruikt naast het mondkapje (Bent u een mondkapje vergeten? Dan kunt u deze kopen bij de receptie.)
Linssen, G.C.M.

dr. G.C.M. Linssen

  • Functie Cardioloog
  • Afdeling / specialisatie Cardiologie
Afspraak maken?

Aandachtsgebieden

  • Hartfalen
  • Echocardiografie
  • Klinische cardiologie
  • Cardiovasculaire research
  • Deelopleiding cardiologie

CV

  • Vanaf 2014 Fellow of the Heart Failure Association of the ESC (FHFA)
  • 28 november 2011 Promotie (Rijksuniversiteit Groningen): BNP and NT-proBNP in cardiovascular diseases
  • Vanaf 2006 Fellow of the European Society of Cardiology (FESC)
  • 1 juli 1996 - heden Cardioloog, ZGT Almelo en Hengelo
  • 1995 en 1996 Cardioloog, Academisch Ziekenhuis Maastricht
  • Specialisatie te Maastricht, 1994 einde opleiding
  • 1989-1990: vooropleiding Interne Geneeskunde, Maaslandziekenhuis Sittard
  • 1982-1988: Geneeskunde studie, Rijksuniversiteit Limburg, Maastricht

 

Nevenfuncties

  • Lid Centrale Wetenschapscommissie ZGT Almelo en Hengelo
  • Hoofd Cardioresearch ZGT
  • Coördinator Klinische Cardiologie, ZGT
  • Voorzitter werkgroep hartfalen ZGT
  • Lid van Raad van Advies, Stichting Hartcentrum Twente
  • 2013 – 2014 voorzitter van de WCN-congrescommissie
  • 2012 – heden bestuurslid van de landelijke werkgroep Hartfalen (NVVC)
  • Voorzitter commissie Orgaan- en Weefseldonatie ZGT, tot 2016
  • Lid Centrale opleidingscommissie ZGT, tot 2015
  • Voorzitter stafcommissie kwaliteit, tot 1 januari 2007
  • 2006-2012: onderzoeker, Thoraxcentrum, UMC Groningen
  • 2006 – 2012: bestuur (secretaris) Werkgroep Cardiologische Centra Nederland (WCN)

 

Samenwerkingsverbanden

 

 

 

Wetenschappelijke publicaties en onderzoeken

  • Differences in guideline-recommended heart failure medication between Dutch heart failure clinics: an analysis of the CHECK-HF registry

    Linssen GCM, Veenis JF, Brunner-La Rocca HP, Pol PEJ van , Engelen DJM, Tooren RM van , .
    Neth Heart J. 2020; 28(6):334-344.

  • Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure

    Solomon SD, Vaduganathan M, Claggett B, Packer M, Zile M, Swedberg K, Rouleau J, Pfeffer M, Desai A, Linssen GCM.
    Circulation 2020; 141(5):352-361.

  • Outcomes in Patients Treated With Thin-Strut, Very Thin-Strut, or Ultrathin-Strut Drug-Eluting Stents in Small Coronary Vessels: A Prespecified Analysis of the Randomized BIO-RESORT Trial

    Buiten RA, Ploumen EH, Zocca P, Heijden LC van der , Kok MM, Danse PW, Schotborgh CE, Scholte M, Man FH da, Linssen GCM.
    JAMA Cardiol. 2019; :doi: 10.1001/jamacardio.2019.1776. [Epub ahead of print].

    Publicatie openen
  • Effects of European Society of Cardiology guidelines on medication profiles after hospitalization for heart failure in 22,476 Dutch patients: from 2001 until 2015

    Kruik-Kollöffel WJ, Linssen GCM, , Kruik HJ, Movig KL, Heintjes EM, Palen J van der .
    Heart Fail Rev. 2019; :doi: 10.1007/s10741-019-09777-2. [Epub ahead of print].

    Publicatie openen
  • Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction: The CHECK-HF Registry.

    Brunner-La Rocca HP, Linssen GCM, Smeele FJ, Drimmelen AA van , Schaafsma HJ, Westendorp PH, Rademaker PC, Kamp HJ van de , Hoes AW, Brugts JJ.
    JACC Heart Fail 2019; Jan;7(1):13-21.

    Publicatie openen
  • Effectiveness of the European Society of Cardiology/Heart Failure Association website 'heartfailurematters.org' and an e-health adjusted care pathway in patients with stable heart failure: results of the 'e-Vita HF' randomized controlled trial

    Wagenaar KP, Broekhuizen BD, Jaarsma T, Kok I, Mosterd A, Willems FF, Linssen GCM, Agema WR, Anneveldt S, Lucas CM.
    Eur J Heart Fail. 2018; :doi: 10.1002/ejhf.1354. [Epub ahead of print].

    Publicatie openen
  • Thin composite wire strut, durable polymer-coated versus ultrathin cobalt-chromium strut, bioresorbable polymer-coated (Orsiro) drug eluting stents in allcomers with coronary artery disease

    Birgelen C von, Zocca P, Buiten RA, Jessurun GA, Schotborgh CE, Roguin A, Danse PW, Benit E, Aminian A, Houwelingen KG van, Anthonio RL, Stoel MG, Somi S, Hartmann M, Linssen GCM.
    Lancet. 2018; 392 (10154):1235-1245.

    Publicatie openen
  • High Bleeding Risk Patients Treated with Very Thin-Strut Biodegradable Polymer or Thin-Strut Durable Polymer Drug-Eluting Stents in the BIO-RESORT Trial

    Zocca P, Kok MM, Heijden LC van der , Danse PW, Schotborgh CE, Scholte M, Hartmann M, Linssen GCM, Doggen CJ, Birgelen C von.
    Cardiovasc Drugs Ther. 2018; :doi: 10.1007/s10557-018-6823-9. [Epub ahead of print].

    Publicatie openen
  • A comparison of the prognostic value of BNP versus NT-proBNP after hospitalisation for heart failure.

    Linssen GCM, Jaarsma T, Hillege HL, Voors AA, Veldhuizen DJ van .
    Neth Heart J. 2018; :doi: 10.1007/s12471-018-1145-x. [Epub ahead of print].

    Publicatie openen
  • High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor: Insights from CHANGE DAPT.

    Zocca P, Kok MM, Heijden LC van der , Houwelingen KG van , Hartmann M, Man FH de , Louwerenburg JH, Knottnerus IL, Linssen GCM.
    Int J Cardiol. 2018; :doi: 10.1016/j.ijcard.2018.03.116. [Epub ahead of print].

    Publicatie openen
  • Bioresorbable Polymer-Coated Orsiro Versus Durable Polymer-Coated Resolute Onyx Stents (BIONYX): Rationale and design of the randomized TWENTE IV multicenter trial.

    Heijden LC van der , Kok MM, Zocca P, Jessurun GA, Schotborgh CE, Roguin A, Benit E, Danse PW, Linssen GCM.
    Am Heart J. 2018; 198(4):25-32.

    Publicatie openen
  • 5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial

    Zocca P, Kok MM, Tandjung K, Danse PW, Jessurun GA, Hautvast RW, Houwelingen KG van , Stoel MG, Schramm AR, Tjon Joe Gin RM, Man FH de, Hartmann M, Louwerenburg JH, Linssen GCM.
    JACC Cardiovasc Interv. 2018; 11(5):462-469.

    Publicatie openen
  • Silent Diabetes and Clinical Outcome After Treatment With Contemporary Drug-Eluting Stents: The BIO-RESORT Silent Diabetes Study.

    Birgelen C von, Kok MM, Sattar N, Zocca P, Doelman C, Kant GD, Löwik MM, Heijden LC van der , Sen H, Linssen GCM.
    JACC Cardiovasc Interv. 2018; 11(5):448-459.

    Publicatie openen
  • Long-Term Outcome of Consecutive Patients With Previous Coronary Bypass Surgery, Treated With Newer-Generation Drug-Eluting Stents

    Heijden LC van der , Kok MM, Zocca P, Sen H, Mariani S, Man FH de, Hartmann M, Linssen GCM.
    J Am Heart Assoc. 2018; : pii: e007212. doi: 10.1161/JAHA.117.007212. [epub ahead of print].

    Publicatie openen
  • Prediabetes and its Impact on Clinical Outcome After Coronary Intervention in a Broad Patient Population

    Kok MM, Birgelen C von , Sattar N, Zocca P, Löwik MM, Danse PW, Linssen GCM.
    EuroIntervention 2018; :doi: 10.4244/EIJ-D-17-01067. [Epub ahead of print].

  • Five-Year Outcome After Implantation of Zotarolimus- and Everolimus-Eluting Stents in Randomized Trial Participants and Nonenrolled Eligible Patients

    Birgelen C von, Heijden LC van der, Basalus MW, Kok MM, Sen H, Louwerenburg HW, Houwelingen KG van , Linssen GCM, Palen J van der .
    JAMA Cardiol 2017; 2(3):268-276.

  • TCT-357 Impact of Gender and Age on 3-Year Clinical Outcome and Chest Pain of Patients With Coronary Artery Disease Treated With Contemporary Drug-Eluting Stents: A Patient-Level Pooled Analysis

    Kok M, Heijden L van der, Lowik M, Zocca P, Doggen CJ, Danse P, Anthonio RL, Hartmann M, Linssen GCM, Maas A, Mehran R, Birgelen C von.
    J Am Coll Cardiol 2016; 68(18S):B146.

    Publicatie openen
  • TCT-170 Clinical Outcome After Myocardial Infarction Treated With Resolute Integrity and Promus Element Stents: Insights From DUTCH PEERS (TWENTE II) Randomized Trial

    Houwelingen KG van, Heijden L van der, Lam MK, Lowik M, Danse P, Tjon Joe Gin RM, Jessurun GA, Anthonio RL, Sen H, Linssen GCM, IJzerman MJ, Doggen CJ, Birgelen C von.
    J Am Coll Cardiol 2016; 68(18S):B70.

    Publicatie openen
  • Long-term outcome and chest pain in patients with true versus non-true bifurcation lesions treated with second-generation drug-eluting stents in the TWENTE trial

    Houwelingen KG van, Heijden LC van der, Lam MK, Kok MM, Löwik MM, Louwerenburg JW, Linssen GCM, IJzerman MJ, Doggen CJ, Birgelen C von.
    Heart Vessels. 2016; 31(11):1731-1739.

    Publicatie openen
  • Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial

    Birgelen C von, Kok MM, Heijden LC van der, Danse PW, Schotborgh CE, Scholte M, Gin RM, Somi S, Houwelingen KG van, Stoel MG, Man FH de, Louwerenburg JH, Hartmann M, Zocca P, Linssen GCM, Palen J van der, Doggen CJ, Löwik MM.
    Lancet 2016; :[Epub ahead of print].

    Publicatie openen
  • Pseudomonas aeruginosa meningitis after visiting a swimming pool a complicated dive: a case report

    Knapen DG, Mulder B, DeSouza F, Linssen GCM, Veneman ThF.
    Neth J Crit Care 2016; :.

    Publicatie openen
  • Two-year outcome after treatment of severely calcified lesions with newer-generation drug-eluting stents in acute coronary syndromes: A patient-level pooled analysis from TWENTE and DUTCH PEERS

    Huisman J, Heijden LC van der , Kok MM, Louwerenburg JH, Danse PW, Jessurun GA, Man FH de, Löwik MM, Linssen GCM, Ijzerman MJ, Doggen CJ, Birgelen C von.
    J Cardiol 2016; pii: S0914-5087(16)30142-3:.

    Publicatie openen
  • Small-vessel treatment with contemporary newer-generation drug-eluting coronary stents in all-comers: Insights from 2-year DUTCH PEERS (TWENTE II) randomized trial

    Heijden LC van der , Kok MM, Danse PW, Schramm AR, Hartmann M, Löwik MM, Linssen GCM, Stoel MG, Doggen CJ, Birgelen C von.
    Am Heart J 2016; 176:28-35.

    Publicatie openen
  • The magnitude and management of chronic heart failure in the netherlands

    Groot S de, Sadacharan S, Linssen GCM.
    Eur J Heart Fail 2016; 18:188, suppl 1.

  • Sex Difference in Chest Pain After Implantation of Newer Generation Coronary Drug-Eluting Stents: A Patient-Level Pooled Analysis From the TWENTE and DUTCH PEERS Trials

    Kok MM, Heijden LC van der, Sen H, Danse PW, Löwik MM, Anthonio RL, Louwerenburg JH, Man FH de, Linssen GCM, IJzerman MJ, Doggen CJ, Maas AH, Mehran R, Birgelen C von.
    JACC Cardiovasc Interv. 2016; 9(6):553-61.

  • Bifurcation treatment with novel, highly flexible drug-eluting coronary stents in all-comers: 2-year outcome in patients of the DUTCH PEERS trial

    Heijden LC van der, Kok MM, Lam MK, Danse PW, Linssen GCM.
    Clin Res Cardiol 2016; 105(3):206-215.

    Publicatie openen
  • Urine measurement indicates the plasma brain natriuretic peptide concentration during optimization of heart failure treatment

    Hahn RG, Jaarsma T, Waldréus N, Linssen GCM.
    Scand J Clin Lab Invest 2015; 17:1-6.

    Publicatie openen
  • Bifurcation treatment with novel, highly flexible drug-eluting coronary stents in all-comers 2-year outcome in patients of the DUTCH PEERS trial

    Heijden LC van der, Kok MM, Lam MK, Danse PW, Schramm AR, Jessurun GA, Tjon Joe Gin RM, Houwelingen KG van, Hautvast RW, Linssen GCM, Sen H, Löwik MM, IJzerman MJ, Doggen CJ, Birgelen C von.
    Clin Res Cardiol 2015; :.

    Publicatie openen
  • Clinical Events and Patient-Reported Chest Pain in All-Comers Treated With Resolute Integrity and Promus Element Stents: 2-Year Follow-Up of the DUTCH PEERS-Randomized Trial

    Heijden LC van der, Lam MK, Danse PW, Jessurun GA, Tjon Joe Gin RM, Houwelingen KG van, Hautvast RW, Linssen GCM, Sen H, Löwik MM, IJzerman MJ, Doggen CJ, Birgelen C von, Anthonio RL, Louwerenburg JH, Man FH de, Stoel MG, Tandjung K.
    JACC Cardiovasc Interv 2015; 8(7):889-99.

    Publicatie openen
  • Clinical outcome of patients with implantation of second-generation drug-eluting stents in the right coronary ostium: Insights from 2-year follow-up of the TWENTE trial

    Lam MK, Sen H, Tandjung K, Löwik MM, Basalus MW, Mewes JC, Stoel MG, Houwelingen KG van, Linssen GCM, IJzerman MJ, Doggen CJ, Birgelen C von.
    Catheter Cardiovasc Interv 2015; 85(4):524-31.

    Publicatie openen
  • Safety of second-generation drug-eluting stents three years after randomised use in the TWENTE trial

    Löwik MM, Lam MK, Sen H, Tandjung K, Houwelingen KG van, Man FH de, Stoel MG, Louwerenburg JH, Linssen GCM, Doggen CJ, Birgelen C von, .
    EuroIntervention. 2015; 10(11):1276-9.

    Publicatie openen
  • Complex patients treated with zotarolimus-eluting resolute and everolimus-eluting Xience V stents in the randomized TWENTE trial: comparison of 2-year clinical outcome.

    Sen H, Lam MK, Tandjung K, Löwik MM, Stoel MG, Man FH de, Louwerenburg JH, Houwelingen GK van, Linssen GCM, Doggen CJ, Basalus MW, Birgelen C von.
    Catheter Cardiovasc Interv. 2015; 85 (1):74-81. doi: 10.1002/ccd.25464. Epub 2014 Mar 14. .

    Publicatie openen
  • Long-term follow-up in optimally treated and stable heart failure patients: primary care vs. heart failure clinic. Results of the COACH-2 study

    Luttik ML, Jaarsma T, Geel PP van, Brons M, Hillege HL, Hoes AW, Jong R de, Linssen GCM, Lok DJ, Berge M, Veldhuisen DJ van.
    Eur J Heart Fail 2014; 16(11):1241-8.

    Publicatie openen
  • Three-year clinical outcome after treatment of chronic total occlusions with second-generation drug-eluting stents in the TWENTE trial

    Houwelingen KG van, Sen H, Lam MK, Tandjung K, Löwik MM, Man FH de, Louwerenburg JH, Stoel MG, Hartmann M, Linssen GCM, Doggen CJ, Birgelen C von.
    Catheter Cardiovasc Interv 2014; :.

    Publicatie openen
  • Impact of previous coronary artery bypass surgery on clinical outcome after percutaneous interventions with second generation drug-eluting stents in TWENTE trial and non-enrolled TWENTE registry

    Sen H, Lam MK, Tandjung K, Löwik MM, Houwelingen KG van, Stoel MG, Louwerenburg HW, Man FH de, Linssen GCM, Grandjean JG, Doggen CJ, Birgelen C von.
    Int J Cardiol 2014; 176(3):885-90. doi: 10.1016/j.ijcard.2014.08.036 Epub 2014 Aug 13.

    Publicatie openen
  • Clinical outcome following second-generation drug-eluting stent use for off-label versus on-label indications

    Sen H, Lam MK, Tandjung K, Basalus MW, Man FH de, Louwerenburg JH, Stoel MG, Houwelingen GK van, Löwik MM, Linssen GCM, Said SA, Nienhuis MB, Verhorst PM, Palen J van der, Birgelen C von.
    EuroIntervention 2014; 10(6):664-71.

  • Coronary artery dominance and the risk of adverse clinical events following percutaneous coronary intervention: insights from the prospective, randomised TWENTE trial (1)

    Lam MK, Tandjung K, Sen H, Basalus MW, Houwelingen KG van, Stoel MG, Louwerenburg JW, Linssen GCM, Said SA, Nienhuis MB, Man FH de, Palen J van der, Birgelen C von.
    EuroIntervention 2014; (9):1-8.

  • Safety of second generation drug-eluting stents three years after randomised use in the TWENTE trial

    Löwik MM, Lam MK, Sen H, Tandjung K, Houwelingen KG van, Man FH de, Stoel MG, Louwerenburg JH, Linssen GCM, Doggen CJ, Birgelen C von.
    EuroIntervention 2014; :.

  • Update Hartfalen en optimaal gebruik van (NT-pro)BNP

    Linssen GCM.
    Analyse 2014; 69:44-49.

  • Coronary artery dominance and the risk of adverse clinical events following percutaneous coronary intervention: insights from the prospective, randomised TWENTE trial

    Lam MK, Tandjung K, Sen H, Basalus MW, Houwelingen KG van, Stoel MG, Louwerenburg JW, Linssen GCM, , Nienhuis MB, Man FH de , Palen J van der, Birgelen J von.
    EuroIntervention 2014; 11 (2):180-7.

    Publicatie openen
  • Clinical outcome of patients with implantation of second-generation drug-eluting stents in the right coronary ostium: insights from 2-year follow-up of the TWENTE trial

    Lam MK, Sen H, Tandjung K, Löwik MM, Basalus MW, Mewes JC, Stoel MG, Houwelingen KG van, Linssen GCM, IJzerman MJ, Doggen CJ, Birgelen C von.
    Catheter Cardiovasc Interv 2014; :Epub Apr 18.

    Publicatie openen
  • Comparison of 3 biodegradable polymer and durable polymer-based drug-eluting stents in all-comers (BIO-RESORT): Rationale and study design of the randomized TWENTE III multicenter trial

    Lam MK, Sen H, Tandjung K, Houwelingen KG van, Vries AG de, Danse PW, Schotborgh CE, Scholte M, Löwik MM, Linssen GCM, IJzerman MJ, Palen J van der, Doggen CJ, Birgelen C von.
    Am Heart J 2014; 167(4):445-51. doi: 10.1016/j.ahj.2013.11.014.

    Publicatie openen
  • Type D, coping and self-care in chronic heart failure patients

    Ree R van der, Schiffer AA, Rodijk E, Weevers M, Linssen GCM.
    J Prec Cardiol 2014; 3:404-411.

  • Complex patients treated with zotarolimus-eluting resolute and everolimus-eluting xience V stents in the randomized TWENTE trial: Comparison of 2-year clinical outcome

    Sen H, Lam MK, Tandjung K, Löwik MM, Stoel MG, Man FH de, Louwerenburg JH, Houwelingen GK van, Linssen GCM, Doggen CJ, Basalus MW, Birgelen C von.
    Catheter Cardiovasc Interv 2014; :doi: 10.1002/ccd.25464 [Epub ahead of print].

    Publicatie openen
  • Highly deliverable third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial

    Birgelen C von, Sen H, Lam MK, Danse PW, Jessurun GA, Hautvast RW, Houwelingen GK van, Schramm AR, Gin RM, Louwerenburg JW, Man FH de, Stoel MG, Löwik MM, Linssen GCM, Said SA, Nienhuis MB, Verhorst PM, Basalus MW, Doggen CJ, Tandjung K.
    Lancet 2014; 383(9915):413-23.

  • Third generation zotarolimus eluting and everolimus eluting stents

    Birgelen C, Sen H, Lam MK, Danse PW, Jessurun GA, Hautvast RW, Houwelingen GK van, Schramm AR, Gin RM, Louwerenburg JW, Man FH de, Stoel MG, Löwik MM, Linssen GCM, Saïd SA, Nienhuis MB, Verhorst PM, Basalus MW, Doggen CJ, Tandjung K.
    Lancet 2014; 383(9915):413-423.

    Publicatie openen
  • Women treated with second generation zotarolimus eluting resolute stents and everolimus eluting xience V stents

    Tandjung K, Basalus MW, Sen H, Stoel MG, Houwelingen KG van, Louwerenburg JH, Man FH de, Linssen GCM, , Kleijne MA, Palen J van der, Birgelen C von.
    Catheter Cardiovasc Interv. 2013; 82(3):396-405.

    Publicatie openen
  • Clinical Outcome Following Stringent Discontinuation of Dual Antiplatelet Therapy After 12 Months in Real-World patients

    Tandjung K, Sen H, Lam MK, Basalus MW, Louwerenburg JH, Stoel MG, Houwelingen KG van, Man FH de, Linssen GCM, , Nienhuis MB, Löwik MM, Verhorst PM, Palen J van der , Birgelen C von.
    J Am Coll Cardiol. 2013; 61(24):2406-16.

    Publicatie openen
  • Type D, coping and self-care in chronic heart failure patients

    Ree R van der, Schiffer AA, Rodijk E, Weevers M, Linssen GCM.
    J Prev Cardiol 2013; 3:404-411.

    Publicatie openen
  • Comparison of eligible non-enrolled patients and the randomised TWENTE trial population treated with Resolute and Xience V drug-eluting stents

    Sen H, Tandjung K, Basalus MW, Löwik MM, Houwelingen GK van, Stoel MG, Louwerenburg HW, Man FH de, Linssen GCM, Nijhuis RLG, Nienhuis MB, Verhorst PM, Palen J van der, Birgelen C von.
    EuroIntervention 2012; 8(6):664-71.

  • Ventricular Tachycardia during treatment with Modafinil for narcolepsy: a case report

    Binnenmars H, Idzerda HHD, Tan HL, Linssen GCM.
    Internat J Clin Med 2012; 3:513-517.

    Publicatie openen
  • Comparison of frequency of periprocedural myocardial infarction in patients with and without Diabetes Mellitus

    Tandjung K, Houwelingen KG van, Jansen H, Linssen GCM, Nijhuis RLG.
    Am J Cardiol 2012; 110:1561-1567.

    Publicatie openen
  • Design and methodology of the COACH-2 (Comparative study on guidelines adherence and patient compliance in heart failure patients) study: HF clinics versus primary care in stable patients on optimal therapy

    Luttik ML, Brons M, Jaarsma T, Hillege HL, Hoes A, Linssen GCM.
    Neth Heart 2012; 20:307-312.

    Publicatie openen
  • A randomized controlled trial in second generation zotarolimus-eluting resolute stents versus everolimus-eluting xience V stants in real-world patients: the Twente trial

    Birgelen C von , Basalus MW, Tandjung K, Linssen GCM, .
     J Am Coll Cardiol 2012; 59:1350-1361.

    Publicatie openen